Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company‚Äôs equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Goto 0, 1, Next
Reported
DateTime
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportFiling
2023-02-14
4:04 pm
Sale
13GArcutis Biotherapeutics, Inc.
ARQT
Point72 Asset Management L.P.1,187,598
1.9%
-1,470,364decrease
(-55.32%)
View
2023-02-09
08:23 am
Purchase
13GArcutis Biotherapeutics, Inc.
ARQT
FMR LLC9,139,173
14.999%
1,594,961increase
(+21.14%)
View
2023-02-08
10:03 am
Purchase
13GArcutis Biotherapeutics, Inc.
ARQT
STATE STREET CORP
STT
3,679,385
6.04%
3,679,385increase
(New Position)
View
2023-02-03
4:27 pm
Purchase
13GArcutis Biotherapeutics, Inc.
ARQT
BlackRock Inc.
BLK
5,214,258
8.6%
900,394increase
(+20.87%)
View
2022-08-26
4:12 pm
Sale
13DArcutis Biotherapeutics, Inc.
ARQT
ORBIMED ADVISORS LLC2,828,356
4.7%
-318,368decrease
(-10.12%)
View
2022-08-09
3:11 pm
Purchase
13DArcutis Biotherapeutics, Inc.
ARQT
Frazier Life Sciences VIII L.P.8,745,318
14.6%
263,411increase
(+3.11%)
View
2022-08-08
4:49 pm
Unchanged
13DArcutis Biotherapeutics, Inc.
ARQT
Bain Capital Life Sciences Fund L.P.2,721,436
4.5%
0
(Unchanged)
View
2022-08-08
4:26 pm
Sale
13DArcutis Biotherapeutics, Inc.
ARQT
ORBIMED ADVISORS LLC3,146,724
5.4%
-387,813decrease
(-10.97%)
View
2022-06-28
4:22 pm
Sale
13DArcutis Biotherapeutics, Inc.
ARQT
ORBIMED ADVISORS LLC3,534,537
6.9%
-306,027decrease
(-7.97%)
View
2022-05-27
4:19 pm
Sale
13DArcutis Biotherapeutics, Inc.
ARQT
Bain Capital Life Sciences Fund L.P.2,721,436
5.3%
-888,360decrease
(-24.61%)
View
2022-04-08
5:20 pm
Sale
13DArcutis Biotherapeutics, Inc.
ARQT
ORBIMED ADVISORS LLC3,840,564
7.6%
-427,000decrease
(-10.01%)
View
2022-02-14
4:27 pm
Purchase
13GArcutis Biotherapeutics, Inc.
ARQT
Point72 Asset Management L.P.2,657,962
5.3%
107,226increase
(+4.20%)
View
2022-02-09
09:09 am
Purchase
13GArcutis Biotherapeutics, Inc.
ARQT
FMR LLC7,544,212
14.999%
999,048increase
(+15.26%)
View
2022-02-03
4:41 pm
Purchase
13GArcutis Biotherapeutics, Inc.
ARQT
BlackRock Inc.
BLK
4,313,864
8.6%
1,418,810increase
(+49.01%)
View
2021-12-15
5:14 pm
Purchase
13GArcutis Biotherapeutics, Inc.
ARQT
Point72 Asset Management L.P.2,550,736
5.1%
2,550,736increase
(New Position)
View
2021-05-12
5:27 pm
Sale
13DArcutis Biotherapeutics, Inc.
ARQT
Frazier Life Sciences VIII L.P.8,481,907
16.9%
-2,084,883decrease
(-19.73%)
View
2021-02-09
11:14 am
Purchase
13DArcutis Biotherapeutics, Inc.
ARQT
Frazier Life Sciences VIII L.P.10,566,790
21.7%
24,000increase
(+0.23%)
View
2021-02-08
9:54 pm
Unchanged
13DArcutis Biotherapeutics, Inc.
ARQT
ORBIMED ADVISORS LLC4,267,564
8.8%
0
(Unchanged)
View
2021-02-08
5:00 pm
Unchanged
13DArcutis Biotherapeutics, Inc.
ARQT
Bain Capital Life Sciences Fund L.P.3,609,796
7.4%
0
(Unchanged)
View
2021-02-08
10:15 am
Purchase
13GArcutis Biotherapeutics, Inc.
ARQT
FMR LLC6,545,164
14.999%
2,486,155increase
(+61.25%)
View
Goto 0, 1, Next